



**Contact:** Santosh Venkatesha  
**Location:** Baltimore, MD  
**Email:** [santosh@i-biomed.com](mailto:santosh@i-biomed.com)  
**Tel:** 410.889.8011  
**Website:** <http://www.i-biomed.com>



## Company Profile

**Industry Sector:** Medical Devices

**Company Overview:** Infinite Biomedical Technologies (IBT) was founded in 1997 and is headquartered in Baltimore, Maryland. IBT is deeply motivated to solve important clinical problems by translating research discoveries into commercially available medical products through device sales and intellectual property licensing. With this 'bench to bedside' philosophy, the company focuses on three distinct business lines: global asphyxia, neurocritical care and intraoperative monitoring, and long-term monitoring. IBT's mission is to become the leading supplier of innovative instrumentation, software, and services for quantitative neurodiagnostics.

**Target Market(s):** Neonatal Intensive Care Unit (NICU) personnel, neonatologists, pediatric neurologists.

## Key Value Drivers

**Technology:** The Neonatal Neurologic Monitor (N2M) is an intuitive and compact neurological device for assessing brain injury in newborns. Intended primarily for NICU nurses and neonatologists, the defining features of this diagnostic device include easy-to-apply specialty electrodes, reliable amplifiers, a video camera, and an easy-to-interpret Cortical Health Index score for brain injury. The device also includes a remote monitoring feature to allow neurologists to review the EEG data from any computer at any item with configurable EEG channels.

**Competitive Advantage:** The N2M device is the only neurologic system with features that satisfy both the NICU staff and the neurologist. No other system matches the reliable continuous monitoring capability or the amalgamation of innovative features provided by the N2M. The N2M system is also the first of its kind to pursue FDA clearance on the innovative CHI/b algorithm.

**Plan & Strategy:** Seeking strategic partnerships & investments to bring technology to market.

\*Technology funded by the NINDS and being commercialized under the NIH-CAP.

## Management

### Leadership:

Ananth Natarajan, MD, CEO  
 Santosh Venkatesha, COO  
 Neil Rothman, PhD, Vice President of Research and Development

### Scientific Collaborators:

Nitish Thakor, PhD  
 Terrie Inder, MD  
 Romergryko Geocadin, MD  
 Daniel Hanley, MD  
 Peter Kaplan, MB, FRCP

## Product Pipeline

The N2M monitor is a two-channel EEG monitor which includes the Cortical Health Index for Babies (CHI/b) algorithm to provide quantitative feedback to clinical personnel on patient neurological status. The N2M monitor also includes a remote monitoring infrastructure and user interface (UI) specifically designed for the neurologist.

